Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
breast cancer
Pharma
PD-1 bispecifics, Enhertu, Regeneron-Hansoh—Fierce Pharma Asia
The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal.
Angus Liu
Jun 6, 2025 7:15am
ASCO: AZ, Daiichi flex Enhertu muscle in 2 cancers
Jun 2, 2025 8:00am
Enhertu, Takeda, Trump—Fierce Pharma Asia
May 9, 2025 6:15am
AZ, Daiichi's Enhertu tops SOC in early-stage breast cancer
May 7, 2025 10:12am
AstraZeneca unfolds 1st TV ad for breast cancer med Truqap
Apr 30, 2025 12:31pm
Angus on Angus: A Fierce oncology discussion
Apr 25, 2025 9:41am
